presentation
case
woman
presented
pulmonary
embolism
taking
without
apparent
complication
estradiol
ortho
mg
norgestimate
cycle
ethinyl
estradiol
followed
drug
combination
lower
dose
ethinyl
estradiol
ortho
lo
ethinyl
estradiol
mo
nonsmoker
lacked
relevant
family
history
vigorously
athletic
one
month
prior
presentation
developed
neck
pain
disc
protrusion
detected
magnetic
resonance
imaging
patient
prescribed
valdecoxib
mg
twice
day
wk
neck
pain
resolved
however
towards
end
treatment
period
developed
pleuritic
chest
shoulder
pain
car
ride
started
cyclobenzaprine
mg
continued
valdecoxib
pain
abated
gradually
however
later
developed
chest
shoulder
pain
diagnosis
left
iliac
vein
thrombosis
bilateral
pulmonary
embolus
based
computed
tomography
scan
heparinized
continued
therapy
warfarin
mg
enoxaparin
mg
despite
scan
performed
later
showed
multiple
pulmonary
embolus
figure
currently
patient
warfarin
mg
daily
completing
warfarin
regimen
warfarin
well
tolerated
otherwise
patient
good
health
discussion
coxibs
selective
inhibitor
increase
risk
myocardial
infarction
stroke
prompting
concern
patient
established
cardiovascular
disease
caution
may
also
extend
individual
predisposed
thrombosis
genetic
environmental
factor
risk
factor
spontaneous
thrombosis
include
oral
contraceptive
genetic
predisposition
hypercoaguable
state
prolonged
period
stasis
least
two
risk
factor
pertained
patient
patient
taking
oral
contraceptive
prior
index
event
albeit
without
recognized
thrombotic
complication
possible
despite
extended
period
apparent
tolerance
embolic
event
solely
related
use
oral
contraceptive
relatively
small
risk
venous
thromboembolism
attributable
oral
contraceptive
use
may
interact
geometrically
similarly
small
absolute
risk
procoagulant
mutation
factor
leiden
however
documented
genetic
risk
factor
abnormality
lupus
anticoagulant
iii
protein
plasma
homocysteine
anticardiolipin
glycoprotein
antibody
prothrombotic
mutation
factor
prothrombin
excluded
remains
possible
patient
genetically
predisposed
thrombosis
mutation
undetermined
factor
finally
prolonged
stasis
occurred
car
trip
may
account
clinical
event
however
absolute
risk
small
patient
made
trip
multiple
occasion
devoid
apparent
clinical
complication
prior
risk
thrombosis
valdecoxib
established
together
propensity
rarely
cause
syndrome
without
mitigating
benefit
traditional
nonsteroidal
drug
led
withdrawal
market
cardiovascular
hazard
coxibs
appears
likely
attributable
suppression
prostacyclin
deletion
prostacyclin
receptor
mouse
spontaneous
thrombosis
rather
enhances
response
thrombotic
stimulus
consistent
fact
cardiovascular
signal
coxib
easily
detected
patient
hemostatic
activation
observed
condition
two
trial
patient
undergoing
cardiopulmonary
bypass
grafting
anecdotally
patient
connective
tissue
disease
although
case
establish
causative
linkage
valdecoxib
clinical
event
manifest
three
potential
risk
factor
combined
oral
contraceptive
prolonged
stasis
coxib
treatment
given
multiplicative
interaction
risk
factor
thromboembolic
disease
apparently
untoward
concurrence
two
contraceptive
pill
frequent
road
trip
preceding
rapid
occurrence
clinical
event
following
initiation
coxib
suggests
causative
link
inhibitor
however
also
remains
formally
possible
temporal
relationship
coincidence
case
report
reported
regulatory
authority
manufacturer
valdecoxib
small
absolute
risk
thrombosis
attributable
oral
contraceptive
prothrombotic
mutation
may
interact
dramatically
selective
inhibitor
may
also
interact
genetic
environmental
factor
predispose
risk
thrombosis